536. Ringman JM, Simmons J.H. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000 Sep 26; 55(6):870-1.
537. Massironi G1, Galluzzi S, Frisoni G.B. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr. 2003 Dec;15(4):377-83
538. Larsson V., Aarsland D., Ballard C., Minthon L. and Londos E. (2010), The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriat. Psychiatry, 25: 1030-1038.
539. Chen H., Zhang S., Hernan M., et al. Weight loss in Parkinson’s disease. Ann Neurol. 2003;53:676-9.
540. Uc E., Struck L., Rodnitzky R., et al. Predictors of weight loss in Parkinson’s disease. Mov Disord. 2006;21:930-6.
541. Markus H., Cox M., Tomkins A. Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity. Clin Sci (Lond).1992;83:199-204
542. Barclay L., High-Fiber D. Low-Saturated-Fat Diet May Protect Against Parkinson's Disease. Am J Clin Nutr. 2007;86:1486-1494.;
543. Alcalay R. N., Gu Y., Mejia-Santana H., Cote L., Marder K. S., Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27:771–774.
544. Gao X., Cassidy A., Schwarzschild M.A. et al. Habitual intake of dietary flavonoids and risk of Parkinson’s disease. Neurology. 2012; 78. (15):1138-45.
545. Powers K., Smith-Weller T., G. M. Franklin, et al. Dietary fats, cholesterol and iron as risk factors for Parkinson’s disease. Parkinsonism and Related Disorders 2009;15:47-52.
546. Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord. 1999;14(1):21-7.
547. Barclay L., High-Fiber D. Low-Saturated-Fat Diet May Protect Against Parkinson's Disease. Am J Clin Nutr. 2007;86:1486-1494.
548. Logroscino G, Marder K, Cote L, et al. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol. 1996;39(1):89-94.
549. Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell CD, Skeaff CM. Effects of total fat intake on body weight. Cochrane Database Syst Rev. 2015; (8):CD011834.
550. Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell CD, Skeaff CM. Effects of total fat intake on body weight. Cochrane Database Syst Rev. 2015; (8):CD011834.
551. Fats and fatty acids in human nutrition: report of an expert consultation. FAO Food and Nutrition Paper 91. Rome: Food and Agriculture Organization of the United Nations; 2010;
552. Agim ZS, Cannon JR. Dietary factors in the etiology of Parkinson's disease. Biomed Res Int. 2015;2015:672838.
553. Wang A, Lin Y, Wu Y, et al. Macronutrients intake and risk of Parkinson's disease: A meta-analysis. Geriatr Gerontol Int. 2015;15(5):606-16
554. Costantini A, Fancellu R. An open-label pilot study with high-dose thiamine in Parkinson's disease. Neural Regen Res. 2016;11(3):406-7. [PMID:27127471];
555. Luong KV, Nguyen LT. The beneficial role of thiamine in Parkinson disease. CNS Neurosci Ther. 2013;19(7):461-8. [PMID:23462281];
556. Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo- controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr. 2013;97(5):1004-13.
557. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 1984; 7: 35-49. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002; 58: 19-32.;
558. Pletscher A., DaPrada M. Pharmacotherapy of Parkinson’s disease: research fr om 1960 to 1991. Acta. Neurol. Scand. Suppl. 1993;146: 26-31.;
559. Yahr M.D., Duvoisin R.C., Schear M.J., Barrett R.E., Hoehn M.M.: Treatment of parkinsonism with levodopa. Arch. Neurol. 1969; 21: 343-354.
560. Cereda E, Barichella M, Pezzoli G. Controlled-protein dietary regimens for Parkinson's disease. Nutr Neurosci. 2010 Feb;13(1):29-32. doi: 10.1179/147683010X12611460763760. PMID: 20132652
561. Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008;23:1146– 1153.
562. Alomar S, King NK, Tam J, Bari AA, Hamani C, Lozano AM. Speech and language adverse effects after thalamotomy and deep brain stimulation in patients with movement disorders: A meta-analysis. Mov Disord. 2017 Jan;32(1):53-63. doi: 10.1002/mds.26924. PMID: 28124434.
563. Bond, Aaron E et al. “Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.” JAMA neurology vol. 74,12 (2017): 1412-1418. doi:10.1001/jamaneurol.2017.3098
564. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson’s disease: one year follow-up of a randomised observer-blind multi centre trial. Acta Neurochir (Wien) 2006;148:1247–1255; discussion 1255.
565. Esselink RA, de Bie RM, de Haan RJ, et al. Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease. Neurology 2009;73:151–153.
566. Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson’s disease. Ann Neurol 2003;53:558–569
567. Odekerken VJ, Boel JA, Schmand BA et al. . GPi vs STN deep brain stimulation for Parkinson disease. Neurology. 2016;86(8):755-761.
568. Deep-Brain Stimulation for Parkinson's Disease Study. G Obeso JA, Olanow CW et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-963.
569. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ et al. . Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry. 2005;76(1):34-39.